Building and leveraging the innovation ecosystem and clusters: universities, startups, accelerators, alliances, and partnerships

A “From the Boardroom” Perspective by the Special Edition Co-Editors

Authors

  • Arthur Boni
  • Moira Gunn

DOI:

https://doi.org/10.5912/jcb963

Abstract

This article focuses on the concepts of ecosystems and clusters, with an emphasis on their importance for building vibrant a vibrant and life science/biopharma industry. We illustrate the underlying principles through work published in academic articles and in the popular press. These are highlighted in brief overviews of several mature and emerging ecosystems in the United States, Europe and Australia. The US perspective is based on our own professional life experiences in Boston, Silicon Valley, San Diego, and Pittsburgh, and, with a shorter preview of Philadelphia where we’ve both done business and have close colleagues.  The article ends with a look to the future in a concluding section titled “What’s Coming Next”.  It is our attempt to look at the future of digitally enhanced collaborative innovation.  This is based on our observations during the first 9 months of the Covid-19 pandemic, social distancing, and working from a distance. We ask, what is the potential impact of these emerging digital technologies on work and advancement of the agenda in the life sciences industries? Will the pandemic transform or disrupt the borders and mode of collaboration of traditional definitions of ecosystems and clusters as we define them today?

Downloads

Published

2021-03-16

Issue

Vol. 26 No. 1 (2021): Building and Leveraging Ecosystems and Clusters

Section

Editorial

License

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.